TLDR:
- SciRhom, a biopharmaceutical company based in Munich, Germany, raised EUR 63M in Series A funding.
- The funding round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners.
In a recent development, SciRhom, a biopharmaceutical company located in Munich, Germany, secured EUR 63M in Series A funding. The funding round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners. Additionally, new investor Bayern Kapital and existing investors like High-Tech Gründerfonds (HTGF) and PhiFund Ventures from New York, USA, also participated in the funding round. This substantial investment will allow SciRhom to accelerate and expand the impact of its therapeutic strategy in autoimmune disorders.
SciRhom is focused on developing therapeutic iRhom2 antibodies and offers proprietary iRhom2-targeting therapies. The company aims to advance its lead antibody program, SR-878, into and through clinical development. Positive preclinical data sets generated in vitro and in animal models of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) have enabled SciRhom to progress its first program to a Phase 1-ready stage.
The company recently obtained its first CTA approval on June 12th, 2024, paving the way for the initiation of a first clinical study in Austria in the latter half of 2024. This study will evaluate safety in healthy volunteers and provide initial evidence of clinical activity in the later part of the study. The leadership team at SciRhom includes Dr. Jens Ruhe as Managing Director and COO, Dr. Jan Poth as Managing Director and CEO, and Dr. Matthias Schneider as CSO.
With the support of prominent investors and a strong leadership team, SciRhom is poised to make significant advancements in the field of biopharmaceuticals and autoimmune disorder treatment.
